HKU Biotech Start-ups Join 2025 BIO Convention USA

Six of the University of Hong Kong's bio-tech start-ups are joining the joint delegation of Hong Kong Science and Technology Parks Corporation (HKSTP) and InvestHK at the Biotechnology Innovation Organization (BIO) International Convention 2025 in Boston, USA during 16-19 June.

As the world's largest and most prestigious biotechnology event, BIO International Convention 2025 gathers over thousands of biotechnology and pharmaceutical leaders for a week of intensive networking, deal-making, and idea exchange.

The six participating bio-tech start-ups of HKU (ie Arbele Limited; Centre for Translational Stem Cell Biology; Centre for Virology, Vaccinology, and Therapeutics; Hong Kong Universal Biologicals; Immuno Cure Holding (HK) Limited; Serilink Biotechnology Company Limited) are diverse innovators across the biomedical and healthcare sectors, pushing the boundaries of medical innovation.

HKU is committed to nurturing a research culture that values excellence and impact through interdisciplinarity, internationalisation and innovation. The University is also eager to bring research results to the wider world through technology transfer, thereby benefiting the public.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.

You might also like